ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Cincinnati, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Cincinnati, OH, USA:

Study of LYL314 in Aggressive Large B-Cell Lymphoma

chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma....

Enrolling
Relapsed Non-Hodgkin Lymphoma
Large B-cell Lymphoma
Drug: Cyclophosphamide
Drug: Fludarabine

Phase 1, Phase 2

Lyell Immunopharma

Cincinnati, Ohio, United States and 16 other locations

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Cincinnati, Ohio, United States and 66 other locations

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic...

Active, not recruiting
Classic Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab

Phase 2

Genmab
Genmab

Cincinnati, Ohio, United States of America and 71 other locations

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: vinblastine
Drug: brentuximab vedotin

Phase 3

Takeda
Takeda

Cincinnati, Ohio, United States and 215 other locations

pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma,....

Enrolling
SLL (Small Lymphocytic Lymphoma)
CLL (Chronic Lymphocytic Leukemia)
Drug: ZE 50-0134

Phase 1

Eilean Therapeutics

Cincinnati, Ohio, United States and 3 other locations

the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas...

Enrolling
Lymphoma, T-Cell
Diffuse Large B Cell Lymphoma
Drug: Enzalutamide
Drug: Tulmimetostat

Phase 1, Phase 2

Novartis
Novartis

Cincinnati, Ohio, United States and 62 other locations

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib...

Active, not recruiting
Lymphoma, Mantle-Cell
Drug: Ibrutinib
Drug: Pirtobrutinib

Phase 3

Loxo Oncology
Loxo Oncology

Cincinnati, Ohio, United States of America and 194 other locations

of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabin...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Cincinnati, Ohio, United States of America and 37 other locations

Locations recently updated

This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma....

Enrolling
Follicular Lymphoma (FL)
Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.
Other: Corticosteroids and/or Radiation (Bridging therapy)

Phase 3

Novartis
Novartis

Cincinnati, Ohio, United States and 34 other locations

weekly for the first 3 months, then every other week for 6 months, then every 28 days until lymphoma progression or unacceptable adverse ev...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Investigator's Choice Chemotherapy
Biological: Epcoritamab

Phase 3

Genmab
Genmab

Cincinnati, Ohio, United States and 212 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems